Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - News - Generic Drugs - November 20, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 60     Next >>     Go To Page:

11/20/17 - Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 Biosimilar Bevacizumab For The Treatment Of Certain Types Of Cancer
By a News Reporter-Staff News Editor at Biotech Business Week Amgen and Allergan plc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin . "ABP 215 has the potential to provide healthcare profession
11/20/17 - Biotech momentum adds more Kosdaq stocks to top 200 [Ventures Africa]
The 10 new Kosdaq-listed firms include biosimilar drug marketer Celltrion Healthcare and antirheumatic drugmaker TissueGene, which made their market debuts in July and earlier this month, respectively, according to data from the Korea Exchange. The firms market cap came to 11 trillion won and 3.6 trillion won, respectively, as of Friday.
11/20/17 - Cipla receives final approval for Generic Dacogen [India Infoline News Service]
Generic Dacogen vial is indicated for treatment of patients with myelodysplastic syndromes Cipla has announced that it has received final approval for its Abbreviated New Drug Application for Decitabine Injection 50 mg single-use sterile vial from the United States Food and Drug Administration to market a generic version of Otsuka America...
11/20/17 - Efficacy and safety maintained in patients who switched from Humira to biosimilar Cyltezo
By a News Reporter-Staff News Editor at Pharma Business Week Boehringer Ingelheim announced one-year data from VOLTAIRE - RA, a pivotal Phase III clinical trial comparing Cyltezo and reference product Humira *. "In addition to the 48- week efficacy results, the adalimumab biosimilar Cyltezo showed equivalent safety and immunogenicity to H
11/20/17 - Findings from University of Szeged Provides New Data about Biosimilars (A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory...
Findings from University of Szeged Provides New Data about Biosimilars. The news correspondents obtained a quote from the research from the University of Szeged, "CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however, the approval was based on randomized clinical trials conducted in patients with rhe
11/20/17 - Glemark Pharma gains 2% following approval from USFDA [India Infoline News Service]
The company received USFDA approval for HAILEY 24 Fe Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd has received ANDA approval by USFDA for HAILEY 24 Fe. The product HAILEY 24 Fe, 1 mg/20 mcg, is the generic version of Loestrin 24 Fe Tablets of Allergan Pharmaceuticals International Ltd.. As per IQVIA sales data fo
11/20/17 - Receipt of Notice That a Patent Infringement Complaint Was Filed Against a Biosimilar Applicant
SUMMARY: The Food and Drug Administration is publishing notice that an applicant for a proposed biosimilar product notified FDA that a patent infringement action was filed in connection with the applicant's biologics license application. Under the Public Health Service Act, an applicant for a proposed biosimilar product or interchangeable product m
11/20/17 - Statement from FDA Commissioner Scott Gottlieb, M.D. on new steps to improve FDA review of shared Risk Evaluation and Mitigation Strategies to...
Statement from FDA Commissioner Scott Gottlieb, M.D. on new steps to improve FDA review of shared Risk Evaluation and Mitigation Strategies to improve generic drug access. By a News Reporter-Staff News Editor at Pharma Business Week To manage the risks associated with drugs, the FDA employs a range of tools. For drugs that are associated with ser
11/19/17 - Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT
ONTRUZANT is the industry s first biosimilar referencing Herceptin i to receive marketing authorization from the European Commission Samsung Bioepis sets an industry record by obtaining European regulatory approval for four biosimilars in just two years. INCHEON, Korea Samsung Bioepis Co., Ltd. today announced the European Commission?
11/18/17 - Generic Drugs Injections/infusions 1. [TendersInfo (India)]
Contract notice: Generic drugs injections/infusions 1.. time limit for receipt of tenders or requests to participate: Date: 15/12/2017 local time: 10:00. conditions for opening tenders date: 15/12/2017 Major organization: VELINDRE NHS TRUST, NHS WALES SHARED SERVICES PARTNERSHIP PROCUREMENT SERVICES Address: Procurement Services 4 Th Floor Companie
11/17/17 - Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - A 2017 Update - Research and Markets
The "Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis- a 2017 Update" report has been added to Research and Markets' offering. Therapeutic antibodies targeting vascular endothelial growth factor or VEGF receptor are a highly successful class of products as evidenced by total sales o
11/17/17 - Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability; Correction
SUMMARY: The Food and Drug Administration is correcting a notice entitled "Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability" that appeared in the Federal Register of November 3, 2017. FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hamps
11/17/17 - FDA Announces Draft Guidance for Biosimilar User Fee Amendments
The Food and Drug Administration announced the availability of a draft guidance for industry entitled "Assessing User Fees Under the Biosimilar User Fee Amendments of 2017.". According to a notice in the Federal Register, this draft guidance concerns FDA's implementation of the Biosimilar User Fee Amendments of 2017 and certain intended changes in.
11/17/17 - Findings in the Area of Adverse Drug Reactions Reported from Auburn University (Brand vs generic adverse event reporting patterns: An authorized...
Findings in the Area of Adverse Drug Reactions Reported from Auburn University. According to news reporting originating in Auburn, Alabama, by NewsRx journalists, research stated, "Some public scepticism exists about generics in terms of whether brand and generic drugs produce identical outcomes. The news reporters obtained a quote from the researc
11/17/17 - Global Oncology Biosimilars Market to Become Become US $17,478.2 Mn over 2017-2022
Albany, NY 11/17/2017 This report on the oncology biosimilars market analyzes the current and future scenario of the global market. Increasing prevalence of cancer, innovation in the development of new drugs, pipeline analysis, and drug class sales during the forecast period. The global oncology biosimilars market report contain an elaborate
11/17/17 - New Remicade Therapy Study Findings Recently Were Reported by Researchers at Radboud University [Long-Term Clinical Outcomes After Switching from...
New Remicade Therapy Study Findings Recently Were Reported by Researchers at Radboud University. According to news reporting originating in Nijmegen, Netherlands, by NewsRx journalists, research stated, "Limited data are available on long-term clinical outcomes regarding the switch from Remicade to the infliximab biosimilar CT-P13 in inflammatory..
11/17/17 - Recent Findings in Biosimilars Described by S. Gran-Ruaz and Colleagues (An overview of biosimilars and non-biologic complex drugs in Europe, the...
Recent Findings in Biosimilars Described by S. Gran-Ruaz and Colleagues. This article defines biosimilars and subsequent entry NBCDs and provides an overview of how these products have been introduced in Europe, the United States, and Canada from a regulatory, health technology, and reimbursement perspective. For more information on this research s
11/17/17 - Sun Pharma reports Q2FY18 results
Mumbai- Sun Pharmaceutical Industries Ltd. reported financials for the second quarter& first half ending September 30th, 2017. Post the implementation of Goods and Service Tax with effect from 01- July-2017, India sales are now reported net of GST while sales in Q2 and H1 last year included excise duty which is now subsumed in GST. India sales at R
11/17/17 - Supply Of Biotherapeutics-support For Development Of Biosimilars (therapeutic Proteins And Monoclonal Antibodies) [TendersInfo (India)]
Request for Proposal are invited for in the areas of: Supply of Biotherapeutics-Support for development of biosimilars for cancer, rheumatoid arthritis and diabetes Support for establishment of: Process Development Laboratory, CMC Facility, GLP Validation Facility, Cell Line Repository Major organization: BIOTECHNOLOGY INDUSTRY REARCH ASSISTANCE...
11/17/17 - UNMC Munroe-Meyer Institute Adds 3 Genetic Counselors
The University of Nebraska Medical Center issued the following news release:. It wasn't too long ago that people meeting Beth Conover thought she was a "generic" counselor. Conover is actually a member of the Munroe-Meyer Institute's team of genetic counselors at the University of Nebraska Medical Center.
11/16/17 - Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2017; New Report Launched: Market Research Reports, Inc. has announced the addition of Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and
Lewes, DE 11/16/2017 The Competitive Intelligence Report "Anti-VEGF& Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis a 2017 Update" provides a competitor evaluation in the field of recombinant antibodies, proteins and vaccines targeting vascular endothelial growth factor or its receptors for treatment of a
11/16/17 - Assessing User Fees Under the Biosimilar User Fee Amendments of 2017; Draft Guidance for Industry; Availability
SUMMARY: The Food and Drug Administration is announcing the availability of a draft guidance for industry entitled "Assessing User Fees Under the Biosimilar User Fee Amendments of 2017." This draft guidance concerns FDA's implementation of the Biosimilar User Fee Amendments of 2017 and certain intended changes in policies and procedures surrounding
11/16/17 - Boehringer Ingelheim receives EU approval for biosimilar Cyltezo [Sudan Tribune]
Boehringer Ingelheim has announced that Cyltezo, its new biosimilar version of adalimumab, has been approved by the European Commission. The regulator has granted marketing authorisation to Cyltezo for the treatment of multiple chronic inflammatory diseases in adults and children, including rheumatoid arthritis, psoriatic arthritis, Crohn`s disease
11/16/17 - British Columbia and Prince Edward Island become the first provinces to add Erelzi (etanercept) to public drug plans for the treatment of multiple inflammatory diseases
-British Columbia and Prince Edward Island are the first provinces to add Erelzi TM to their public drug plans for the treatment of multiple inflammatory diseases, respectively on November 14 and November 27. The two provincial listings follow the conclusion of an agreement between the pan- Canadian Pharmaceutical Alliance and Sandoz Canada, allowi
11/16/17 - Dr. Reddy's Laboratories announces the launch of Clofarabine Injection in the U.S. Market
Hyderabad, India and Princeton, NJ, USA- Dr. Reddy's Laboratories Ltd announced today that it has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar Injection in the United States market, approved by the U.S. Food& Drug Administration. Dr. Reddy's Laboratories' Clofarabine Injection is available in single-dose, 20 mL
Articles(s): 1 - 25 of 60     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415